Drugs, sex, money and power: An HPV vaccine case study
Authors:
- Marion HaasMHMarion Haas
- Toni AshtonTAToni Ashton
- Kerstin BlumKBKerstin Blum
- Terkel ChristiansenTCTerkel Christiansen
- Elena ConisECElena Conis
- Luca CrivelliLCLuca Crivelli
- Meng Kin LimMLMeng Kin Lim
- Melanie LisacMLMelanie Lisac
- Margaret MacAdamMMMargaret MacAdam
- Sophia SchletteSSSophia Schlette
- 1 October 2009
- journal article
- research article
- Published by Elsevier in Health Policy
- Vol. 92 (2-3) , 288-295
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The Australian funding debate on quadrivalent HPV vaccine: A case study for the national pharmaceutical policyHealth Policy, 2008
- Human Papillomavirus Vaccination — Reasons for CautionNew England Journal of Medicine, 2008
- The predicted impact of vaccination on human papillomavirus infections in AustraliaInternational Journal of Cancer, 2008
- Rates of Human Papillomavirus Vaccination, Attitudes About Vaccination, and Human Papillomavirus Prevalence in Young WomenObstetrics & Gynecology, 2008
- Human papillomavirus infection: Epidemiology and pathophysiologyGynecologic Oncology, 2007
- Human papillomavirus, vaccines and women's health: questions and cautionsCanadian Medical Association Journal, 2007
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004
- The causal relation between human papillomavirus and cervical cancerJournal of Clinical Pathology, 2002
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI: Journal of the National Cancer Institute, 1995
- Natural History of Cervical Intraepithelial NeoplasiaInternational Journal of Gynecological Pathology, 1993